natgillin/translations-raw huggingface dataset:
Rateforskel (95 % CI)5
Rate Difference (95% CI)5
Raten af behandlingssvigt ved brug af samme sammensatte endepunkt med centralt aflæst BPAR var 1,9 % i Envarsus-gruppen og 3,7 % i Prograf-gruppen (95 % konfidensinterval [-6,51 %, 2,31 %]).
The treatment failure rate using the same composite end-point with centrally read BPAR was 1.9% in the Envarsus group and 3.7% in the Prograf group (95% confidence interval [-6.51%, 2.31%]).
Raten af bekræftet hypoglykæmi var lavere med Xultophy end med insulin degludec uanset den glykæmiske kontrol, se figur 1.
Rates of confirmed hypoglycaemia were lower with Xultophy than with insulin degludec irrespective of the glycaemic control, see Figure 1.
Raten for 3 års sygdomsfri overlevelse var 71 % for XELOX versus 67 % for 5- FU/LV.
The 3 year DFS rate was 71% for XELOX versus 67% for 5-FU/LV.
Raten for 3 års sygdomsfri overlevelse var 71 % for XELOX versus 67% for 5- FU/LV.
The 3 year DFS rate was 71% for XELOX versus 67% for 5-FU/LV.
Raten for cCCyR i SPRYCEL- og imatinib-gruppen inden for 3 måneder (54% og 30%), 6 måneder (70% og 56%), 9 måneder (75% og 63%), 24 måneder (80% og 74%), 36 måneder (83% og 77%),
The rates of cCCyR in the SPRYCEL and imatinib treatment groups, respectively, within 3 months (54% and 30%), 6 months (70% and 56%), 9 months (75% and 63%), 24 months (80% and 74%),
Raten for MMR på specifikke tidspunkter er vist grafisk i Figur 2.
MMR rates by specific timepoint are displayed graphically in Figure 2.
Raten for MMR til enhver tid for hver risikogruppe, defineret ved Hasford-score, var større i SPRYCEL-gruppen end i imatinib-gruppen (lav risiko: henholdsvis 90% og 69%; middel risiko: henholdsvis 71% og 65%; høj risiko: 67% og 54%).
The rate of MMR at any time in each risk group determined by Hasford score was higher in the SPRYCEL group compared with the imatinib group (low risk: 90% and 69%; intermediate risk: 71% and 65%; high risk: 67% and 54%, respectively).
Raten for MMR var konsekvent højere hos dasatinib-behandlede patienter sammenlignet med imatinib-behandlede patienter.
Rates of MMR were consistently higher in dasatinib-treated patients compared with imatinib-treated patients.
Raten for MMR ved 12, 24, 36, 48, 60 og 72 måneder er præsenteret i tabel 5.
The MMR rate at 12, 24, 36, 48, 60 and 72 months is presented in Table 5.
Raten for natlige hypoglykæmiske hændelser var den samme ved behandling med Xultophy og insulin degludec.
The rate of nocturnal hypoglycaemic events was similar with Xultophy and insulin degludec treatment.
Raten for seponering af kortikosteroider eller immunmodulerende lægemidler er vist i tabel 15.
Rates of discontinuation of corticosteroids or immunomodulators are presented in Table 15.
Raten for seponering af kortikosteroider eller immunmodulerende lægemidler er vist i tabel 20.
Rates of discontinuation of corticosteroids or immunomodulators are presented in Table 20.
Raten for seponering af kortikosteroider eller immunmodulerende lægemidler er vist i tabel 22.
Rates of discontinuation of corticosteroids or immunomodulators are presented in Table 22.
Raten per 1.000 kvindeår efter 5 år var 2,34 i bazedoxifen 20 mg- gruppen og 1,56 i placebo-gruppen (relativ risiko 1,50).
The rate per 1,000 women-years at 5 years was 2.34 in the bazedoxifene 20 mg group and 1.56 in the placebo group (relative risk 1.50).
Raten pr. patienteksponeringsår (procentdel af patienterne) for alvorlig hypoglykæmi defineret som en episode, der kræver hjælp fra en anden person, var 0,01 (2 patienter ud af 825) for Xultophy, 0,01 (2 patienter ud af 412) for insulin degludec og 0,00 (0 patienter ud af 412) for liraglutid.
The rate per patient year of exposure (percentage of patients) of severe hypoglycaemia defined as an episode requiring assistance of another person was 0.01 (2 patients out of 825) for Xultophy, 0.01 (2 patients out of 412) for insulin degludec and 0.00 (0 patients out of 412) for liraglutide.
Rater for forsøgspersoner med PRNT50≥1:10
Rate of subjects with PRNT50≥1:10
Rater for forsøgspersoner med PRNT50≥1:10 og GMT’er efter 2, 6, 12, 24 og 36 måneder er sammenfattet i tabel 3 for ITT-populationen.
Rates of subjects with PRNT50≥1:10 and GMTs at Months 2, 6, 12, 24 and 36 are summarized in Table 3 for the ITT population.
Rater for klinisk remission og klinisk respons (defineret som reduktion i PCDAI-score på mindst 15 point fra baseline) er vist i tabel 14.
Clinical remission and clinical response (defined as reduction in PCDAI score of at least 15 points from Baseline) rates are presented in Table 14.
Rater for klinisk remission og klinisk respons (defineret som reduktion i PCDAI-score på mindst 15 point fra baseline) er vist i tabel 19.
Clinical remission and clinical response (defined as reduction in PCDAI score of at least 15 points from Baseline) rates are presented in Table 19.
Rater for klinisk remission og klinisk respons (defineret som reduktion i PCDAI-score på mindst 15 point fra baseline) er vist i tabel 21.
Clinical remission and clinical response (defined as reduction in PCDAI score of at least 15 points from Baseline) rates are presented in Table 21.
Rater for vedligeholdelse af remission- og respons er vist i Tabel 17.
Maintenance of remission and response rates are presented in Table 17.
Rater for vedligeholdelse af remission- og respons er vist i Tabel 19.
Maintenance of remission and response rates are presented in Table 19.
Raterne for klinisk remission forblev forholdvis konstante uanset tidligere TNF-antagonist- eksposition.
Clinical remission results remained relatively constant irrespective of previous TNF-antagonist exposure.
Raterne for klinisk remission forblev forholdvis konstante uanset tidligere TNF-antagonist-eksposition.
Clinical remission results remained relatively constant irrespective of previous TNF antagonist exposure.
Raterne for virusrecidiv er beregnet med patienter med ikke-detekterbart (eller ubekræftet detekterbart) HCV-RNA ved behandlingsafslutning (EOT) som nævner.
Viral relapse rates are calculated with a denominator of patients with undetectable (or unconfirmed detectable) HCV RNA at EOT.
Raterne for virusrecidiv er beregnet med patienter med ikke-detekterbart HCV-RNA ved EOT og med mindst én opfølgende måling af HCV-RNA som nævner.
Viral relapse rates are calculated with a denominator of patients with undetectable HCV RNA at EOT and with at least one follow-up HCV RNA assessment.
ratio
Ratio
ratio (95% CI)
Unstratified Hazard Ratio (95% CI)
Ratio for AUC (13 - 17 år/voksne), koncentrationen ved afslutning på infusion og koncentrationen ved midtpunktet af doseringsintervallet var henholdsvis 0,99, 1,20 og 0,84.
The ratios (13 to 17 years/Adults) for AUC, the end of infusion concentration and the concentration at the midpoint of the dosing interval were 0.99, 1.20, and 0.84, respectively.
Ratio mellem behandlings- effekt og risiko
Treatment Effect Hazard Ratio
Ratio versus VI
Ratio vs VI 95% CI
Ratio: 0,27 [0,18; 0,41]
Ratio: 0.27 [0.18;0.41]
Ratio: 0,29 [0,13; 0,65]
Ratio: 0.29 [0.13;0.65]
Ratio: 0,63 [0,49; 0,81]
Ratio: 0.63 [0.49;0.81]
Ratio: 0,64 [0,30; 1,37]
Ratio: 0.64 [0.30; 1.37]
Ratio: 0,64 [0,42; 0,98]
Ratio: 0.64 [0.42; 0.98]
Ratio: 0,66 [0,49; 0,88]
Ratio: 0.66 [0.49; 0.88]
Ratio: 0,67 [0,43; 1,06]
Ratio: 0.67 [0.43;1.06]
Ratio: 0,68 [0,52; 0,89]
Ratio: 0.68 [0.52;0.89]
Ratio: 0,75 [0,58; 0,99]
Ratio: 0.75 [0.58; 0.99]
Ratio: 0,75 [0,59; 0,96]
Ratio: 0.75 [0.59; 0.96]
Ratio: 0,77 [0,44; 1,35]
Ratio: 0.77 [0.44; 1.35]
Ratio: 0,80 [0,49; 1,30]
Ratio: 0.80 [0.49;1.30]
Ratio: 0,82 [0,64; 1,04]
Ratio: 0.82 [0.64; 1.04]
Ratio: 0,82 [0,69; 0,99]
Ratio: 0.82 [0.69; 0.99]
Ratio: 0,86 [0,58; 1,28]
Ratio: 0.86 [0.58; 1.28]
Ratio: 0,91 [0,76; 1,09]
Ratio: 0.91 [0.76;1.09]
Ratio: 0,98 [0,80; 1,20]
Ratio: 0.98 [0.80; 1.20]
Ratio: 1,00 [0,76; 1,32]
Ratio: 1.00 [0.76;1.32]
Ratio: 1,03 [0,75; 1,40]
Ratio: 1.03 [0.75; 1.40]
Ratio: 1,07 [0,89; 1,28]
Ratio: 1.07 [0.89; 1.28]
Ratio: 1,10 [0,79; 1,52]6
Ratio: 1.10 [0.79; 1.52]6
Ratio: 1,18 [0,66; 2,12]6
Ratio: 1.18 [0.66; 2.12]6
Ratio: 1,43 [1,07; 1,92]
Ratio: 1.43 [1.07;1.92]
Ratio: 1,93 [0,90; 4,10]
Ratio: 1.93 [0.90; 4.10]
Ratio: 2,17 [1,59; 2,94]
Ratio: 2.17 [1.59;2.94]
Ratio: 3,81 [2,40; 6,05]
Ratio: 3.81 [2.40; 6.05]
Ratioen for blod/plasma- koncentrationen hos mennesker var 0,5-0,7, og det peger på, at dasabuvir fortrinsvis fordeles i plasmakompartmentet i helblod.
The blood to plasma concentration ratios in human ranged from 0.5 to 0.7 indicating that dasabuvir was preferentially distributed in the plasma compartment of whole blood.
Ratioen for blod/plasma- koncentrationen hos mennesker var 0,6-0,8, og det indikerer, at ombitasvir og paritaprevir fortrinsvis fordeles i plasmakompartmentet i helblod.
The blood to plasma concentration ratios in humans ranged from 0.6 to 0.8 indicating that ombitasvir and paritaprevir were preferentially distributed in the plasma compartment of whole blood.
Ratioerne for geometriske mindste kvadraters farmakokinetiske middelværdier ved måned 6 i forhold til baseline var 107 %, 100 % og 104 % for henholdsvis genfinding, AUCt og AUC.
The ratios of geometric least-square means of month 6-to-baseline pharmacokinetic were 107%, 100% and 104% for recovery, AUCt and AUC, respectively.
Ratiograstim 30 mio.
NAME OF THE MEDICINAL PRODUCT
Ratiograstim 48 mio.IE/0,8 ml injektions-/infusionsvæske, opløsning
Ratiograstim 48 MIU/0.8 mL solution for injection or infusion
Ratiograstim bør ikke fortyndes i natriumchloridinfusionsvæske.
Ratiograstim should not be diluted with sodium chloride solution.
Ratiograstim er en injektions- og infusionsvæske i en fyldt injektionssprøjte med eller uden sikkerhedsanordning.
Ratiograstim is a solution for injection or infusion in a pre-filled syringe with or without safety device.
Ratiograstim er et »biosimilært« lægemiddel.
Ratiograstim is a ‘biosimilar’ medicine.
Ratiograstim er ikke undersøgt hos gravide kvinder.
Ratiograstim has not been tested in pregnant women.
Ratiograstim indeholder ikke konserveringsmiddel.
Ratiograstim does not contain any preservative.
Ratiograstim indeholder sorbitol og natrium.
Ratiograstim contains sorbitol and sodium
Ratiograstim kan bruges ved følgende lidelser:
Ratiograstim is useful in several different conditions, which are:
Ratiograstim kan fortyndes efter behov med 50 mg/ml (5 %) glucose infusionsvæske.
If required, Ratiograstim may be diluted in glucose 50 mg/mL (5 %) solution for infusion.
Ratiograstim og kemoterapi
Ratiograstim and chemotherapy
Ratiograstim og knoglemarvstransplantation
Ratiograstim and bone marrow transplantation
Ratiograstim og lavt antal hvide blodlegemer (neutropeni) hos patienter med hiv-infektion
Ratiograstim and neutropenia in patients with HIV infection
Ratiograstim og meget lavt antal hvide blodlegemer (svær kronisk neutropeni)
Ratiograstim and severe chronic neutropenia
Rationalet for behandling består i genopretning af den galdesyreafhængige komponent af galdeflowet, hvorved der kan ske en genopretning af galdesekretion og galdeelimination af toksiske metabolitter, inhibition af produktion af toksiske galdesyremetabolitter ved negativ feedback på cholesterol 7α- hydroxylase, som er det hastighedsbegrænsende enzym i galdesyresyntesen, samt forbedring af patientens ernæringsmæssige status ved at korrigere den intestinale malabsorption af fedt og fedtopløselige vitaminer.
The rational basis for treatment consists of restoration of the bile acid- dependent component of bile flow enabling restoration of biliary secretion and biliary elimination of toxic metabolites; inhibition of the production of the toxic bile acid metabolites by negative feedback on cholesterol 7α-hydroxylase, which is the rate-limiting enzyme in bile acid synthesis; and improvement of the patient’s nutritional status by correcting intestinal malabsorption of fats and fat-soluble vitamins.
Rationalet for behandling består i genopretning af den galdesyreafhængige komponent af galdeflowet, hvorved der kan ske en genopretning af galdesekretion og galdeelimination af toksiske metabolitter, inhibition af produktion af toksiske galdesyremetabolitter ved negativ feedback på cholesterol 7α-hydroxylase, som er det hastighedsbegrænsende enzym i galdesyresyntesen, samt forbedring af patientens ernæringsmæssige status ved at korrigere den intestinale malabsorption af fedt og fedtopløselige vitaminer.
The rational basis for treatment consists of restoration of the bile acid- dependent component of bile flow enabling restoration of biliary secretion and biliary elimination of toxic metabolites; inhibition of the production of the toxic bile acid metabolites by negative feedback on cholesterol 7α-hydroxylase, which is the rate-limiting enzyme in bile acid synthesis; and improvement of the patient’s nutritional status by correcting intestinal malabsorption of fats and fat-soluble vitamins.
ratiopharm
Sildenafil ratiopharm
ratiopharm UK Ltd, United Kingdom Tel: +44 239 238 6330
Ireland ratiopharm UK Ltd, United Kingdom Tel: +44 239 238 6330
rative syg-
Pancytopaenia;
Ravfarvet flerdosis-hætteglas (glas) lukket med gummiprop og forseglet med en foldet aluminiums- hætte.
Multi-dose amber-coloured glass injection vials closed with rubber stopper and sealed with an aluminium crimped top.
Ravfarvet fyldt kanylefri oral sprøjte (polypropylen) med stempel (polypropylen) og hætte (højdensitets polyethylen), pakket i en beskyttende plastictube med hætte.
Amber, pre-filled needle-free oral syringe (polypropylene) with plunger (polypropylene) and end cap (high density polyethylene) packed in a protective, capped plastic tube.
Ravfarvet glasflaske med hvidt børnesikret polypropylenlåg med en induktionsforsegling af polyethylen, indeholdende 5 eller 20 kapsler.
Amber glass bottle with white polypropylene child-resistant screw cap equipped with an induction seal of polyethylene containing 5 or 20 capsules.
Ravfarvet hætteglas (type I)
Vial (glass)
ravgul glasflaske (type III)
amber glass bottle (type III),
Ravgul glasflaske med en polyethylen Luer-mundstykke og et forseglet polypropylen børnesikret låg indeholdende 7,5 ml eller 20 ml.
Amber glass bottle with a polyethylene Luer adapter and a tamper-proof polypropylene child resistant closure containing 7.5 ml or 20 ml.
Ravicti anvendes hos patienter, der mangler et eller flere følgende enzymer: carbamoylphosphatsyntetase-I, ornithincarbamoyltransferase, argininosuccinatsynthetase, argininosuccinatlyase, arginase I og ornithintranslocase.
Ravicti is used in patients who lack one or more of the following enzymes: carbamoyl phosphate synthase-I, ornithine carbamoyltransferase, argininosuccinate synthetase, argininosuccinate lyase, arginase I and ornithine translocase.
Ravicti er blevet sammenlignet med natriumphenylbutyrat (et andet lægemiddel til behandling af forstyrrelser i urincyklus) i en undersøgelse med deltagelse af 88 voksne med forstyrrelse i urincyklus.
Ravicti has been compared with sodium phenylbutyrate (another medicine used to treat urea cycle disorders) in a study involving 88 adults with urea cycle disorders.
Ravicti er et depotpræparat, hvilket betyder, at det aktive stof frigives jævnt dagen igennem.
Ravicti is a sustained-release medicine, meaning the active substance is released evenly during the day.
Ravicti er et lægemiddel til langtidsbehandling af forstyrrelser i urinstofcyklus hos voksne og børn over to måneder, når sygdommen ikke kan håndteres ved kostændringer alene.
Ravicti is a medicine used long-term to manage urea-cycle disorders in adults and children from the age of two months, when the diseases cannot be managed by changes in their diet alone.
RAVICTI er indiceret som tillægsbehandling med henblik på kronisk behandling af voksne og pædiatriske patienter ≥2 måneder med urinstofcyklus-defekter (UCD'er), herunder defekter i carbamylfosfat-syntase I (CPS), ornithintranscarbamylase (OTC), argininoravsyre-syntetase (ASS), argininoravsyrelyase (ASL), arginase I (ARG) og ornithin-translokase-mangel hyperornithinæmi- hyperammoniæmi homocitrullinuri-syndrom (HHH), som ikke alene kan behandles ved begrænsning af protein i kosten og/eller tilskud af aminosyrer.
RAVICTI is indicated for use as adjunctive therapy for chronic management of adult and paediatric patients ≥2 months of age with urea cycle disorders (UCDs) including deficiencies of carbamoyl phosphate-synthase-I (CPS), ornithine carbamoyltransferase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), arginase I (ARG) and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.
Ravicti fås som en væske (1,1 g/ml), der enten indtages gennem munden eller gennem en sonde, der fra næsen føres ned i mavesækken eller gennem maveskindet til mavesækken.
Ravicti is available as a liquid (1.1 g/ml) to be taken by mouth, or through a tube that goes from the nose to the stomach or through the belly into the stomach.
Ravicti glycerolphenylbutyrat
Ravicti glycerol phenylbutyrate
RAVICTI indeholder:
What RAVICTI contains
RAVICTI kan blandes med en lille smule blød mad, såsom ketchup, ernæringspræparat, æblemos eller squash.
RAVICTI can be added to a small amount of soft foods, such as ketchup, medical formulas, apple sauce or squash.
RAVICTI kan blandes med en lille smule æblemos, ketchup eller squash, og blandingen skal anvendes inden for 2 timer ved opbevaring ved stuetemperatur (25° C).
RAVICTI may be added to a small amount of apple sauce, ketchup, or squash and should be used within 2 hours when stored at room temperature (25° C).
Ravicti må ikke anvendes til behandling af pludselig stigning i blodets ammoniakindhold (akut hyperammonæmi).
Ravicti must not be used for the treatment of acute hyperammonaemia (sudden rise of blood ammonia levels).
RAVICTI skal anvendes sammen med en særlig kostplan med lavt proteinindhold.
RAVICTI must be used with a special low protein diet.
Ravicti var påvist som effektivt til at nedsætte blodets ammoniakindhold ved forstyrrelser i urincyklus.
Ravicti was shown to be effective in reducing the blood level of ammonia in patients with urea cycle disorders.
RAVICTIs sikkerhed og virkning til behandling af patienter med N-acetylglutamat-syntetase (NAGS) og CITRIN (citrullinæmi type 2-) defekt er ikke klarlagt.
The safety and efficacy of RAVICTI for the treatment of patients with N-acetylglutamate synthase (NAGS) and CITRIN (citrullinaemia type 2) deficiency have not been established.
Ravsyre Natriumhydroxid Saccharose Polysorbat 20
Succinic acid Sodium hydroxide Sucrose Polysorbate 20
Ravsyre, natriumhydroxid, saccharose, polysorbat 20.
Succinic acid, sodium hydroxide, sucrose, polysorbate 20.
RAV’er ved baseline havde ingen relevant indvirkning på SVR12-raten hos patienter, der var inficeret med HCV-genotype 1, 2, 4, 5 eller 6, som opsummeret i tabel 6.
Baseline RAVs had no relevant impact on SVR12 rates in patients infected with genotype 1, 2, 4, 5 and 6 HCV, as summarised in Table 6.
Raxone er et "hybridt lægemiddel".
Raxone is a ‘hybrid medicine’.
Raxone er et lægemiddel til behandling af nedsat syn hos voksne og unge over 12 år med den arvelige sygdom Lebers hereditære opticus-neuropati (LHON), der er kendetegnet ved fremadskridende synstab.
Raxone is a medicine used to treat visual impairment in adults and adolescents aged 12 years and over with Leber’s hereditary optic neuropathy (LHON), an inherited disease characterised by progressive loss of sight.
Raxone er godkendt under "særlige omstændigheder".
Raxone has been authorised under ‘exceptional circumstances’.
Raxone indeholder farvestoffet sunset yellow (E110).
Raxone contains a colourant called “sunset yellow” (also called E110).
Raxone indeholder sukkerarten lactose.
Raxone contains lactose (a type of sugar).
Raxone kan gå over i modermælken.
Raxone may pass into the mother’s milk.
Raxone leveres i hvide plastflasker.
Raxone is supplied in white plastic bottles.
Raxone påvirker ikke eller kun i ubetydelig grad evnen til at føre motorkøretøj eller betjene maskiner.
Raxone has no or negligible influence on the ability to drive and use machines.
Raxone, filmovertrukne tabletter, 150 mg
Raxone 150 mg film-coated tablets
Raxone, filmovertrukne tabletter, 150 mg idebenon
Raxone 150 mg film-coated tablets idebenone
Raxone, filmovertrukne tabletter, er orange, runde tabletter, diameter 10 mm, med Santheras logo præget på den ene side og "150" på den anden side.
Raxone film-coated tablets are orange, round tablets of 10 mm diameter, engraved with the Santhera logo on one side and ‘150’ on the other side.
Raxone, filmovertrukne tabletter, skal synkes hele med vand.
Raxone film-coated tablets should be swallowed whole with water.
Raynauds fænomen, kolde hænder og fødder
Raynaud's phenomenon, cold hands and feet.
Raynauds syndrom (kredsløbslidelse, der rammer fingre og tæer)
Raynaud's syndrome (circulation disorder affecting the fingers and toes)
Raynauds syndrome, rødmen, bleghed
Raynaud’s disease, flushing, pallor
RBV† i 12 eller
with or without
RCC-klinisk studie 1
RCC Clinical Trial 1
RCC-klinisk studie 2
RCC Clinical Trial 2
RCC-klinisk studie 2 var et randomiseret, dobbelt-blindt, multi-centerstudie med ambulante patienter med henblik på at evaluere effekten, sikkerheden og farmakokinetikken ved tre dosisniveauer af temsirolimus, når det blev givet til tidligere behandlede patienter med fremskreden renalcellekarcinom.
RCC Clinical Trial 2 was a randomised, double-blind, multi-centre, outpatient trial to evaluate the efficacy, safety, and pharmacokinetics of three dose levels of temsirolimus when administered to previously treated patients with advanced renal cell carcinoma.
RCC: studie CA209025 og CA209009
RCC: studies CA209025 and CA209009
RCTU-score
RCTU score
RCTU-score 2 i et eller alle af de
RCTU score 2 in any or all of the
RD (95 % CI) vs placebo
RD (95% CI) vs Placebo
Rd-arma (N = 396)
Rd arma (N = 396)
re
nger
re re
ger ger
Re- administration efter en svær reaktion bør foretages med forsigtighed og under nøje overvågning af den behandlende læge.
Re-administration after a severe reaction should be carried out with caution and close monitoring by the treating physician.
Re-infarkt
Re-infarction
Re-infestation med bændelorm kan ske, med mindre man kontrollerer tilstedeværelsen af mellemværter som bl.a. lopper og mus.
Tapeworm infestation may reoccur unless control of intermediate hosts such as fleas, mice etc. is undertaken.
RE-LY-studiet viste, at dabigatranetexilat 110 mg 2 gange dagligt er non-inferior til warfarin ved forebyggelse af apopleksi og systemisk emboli hos patienter med atrieflimren og medfører en reduceret risiko for intrakraniel blødning, totalblødning og alvorlige blødninger.
The RE-LY study demonstrated that dabigatran etexilate, at a dose of 110 mg twice daily, is non-inferior to warfarin in the prevention of stroke and SEE in subjects with atrial fibrillation, with a reduced risk of ICH, total bleeding and major bleeding.
RE-LY-studiet viste, at dabigatranetexilate 110 mg 2 gange dagligt er non-inferior til warfarin ved forebyggelse af apopleksi og systemisk emboli hos patienter med atrieflimren og medfører en reduceret risiko for intrakraniel blødning, totalblødning og alvorlige blødninger.
The RE-LY study demonstrated that dabigatran etexilate, at a dose of 110 mg twice daily, is non-inferior to warfarin in the prevention of stroke and SEE in subjects with atrial fibrillation, with a reduced risk of ICH, total bleeding and major bleeding.
RE-MEDY viste, at behandling med dabigatranetexilat 150 mg 2 gange dagligt er non-inferior i forhold til warfarin; non-inferioritetsmargin: 2,85 for hazard ratio og 2,8 i risiko-forskel.
RE-MEDY demonstrated that treatment with dabigatran etexilate 150 mg twice daily was non-inferior to warfarin (non-inferiority margin 2.85 for hazard ratio and 2.8 for risk difference).
RE-MEDY viste, at behandling med dabigatranetexilat 150 mg 2 gange dagligt er non-inferior i forhold til warfarin; non-inferioritetsmargin: 2,85 for hazard ratio og 2,8 i risiko-forskel.
RE-MEDY demonstrated that treatment with dabigatran etexilate 150 mg twice daily was non-inferior to warfarin non-inferiority margin: 2.85 for hazard ratio and 2.8 for risk difference).
RE-MODEL (knæ)
RE-MODEL (knee)